Scott Reents's most recent trade in Abbvie Inc was a trade of 17,644 Common Stock, $0.01 par value done at an average price of $212.3 . Disclosure was reported to the exchange on March 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 212.34 per share. | 14 Mar 2025 | 17,644 | 11,577 (0%) | 0% | 212.3 | 3,746,527 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 10,973 | 29,221 (0%) | 0% | 205.0 | 2,249,684 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 27,343 | 27,343 | - | - | Option (Right to buy) | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 8,912 | 32,586 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 7,608 | 40,194 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 5,845 | 21,276 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 2,398 | 23,674 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 14,140 | 17,380 | - | - | Option (Right to buy) | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 177.44 per share. | 23 Feb 2024 | 14,140 | 27,065 (0%) | 0% | 177.4 | 2,509,002 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.36 per share. | 23 Feb 2024 | 14,140 | 41,205 (0%) | 0% | 61.4 | 867,630 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 178.99 per share. | 23 Feb 2024 | 11,634 | 15,431 (0%) | 0% | 179.0 | 2,082,370 | Common Stock, $0.01 par value |
| AbbVie | Reents Scott | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 31,520 | 31,520 | - | - | Option (Right to buy) | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 11,800 | 12,609 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 8,912 | 27,065 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,146 | 15,755 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Reents Scott | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 2,398 | 18,153 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 153.06 per share. | 28 Feb 2023 | 15,092 | 1,659 (0%) | 0% | 153.1 | 2,309,982 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 154.28 per share. | 28 Feb 2023 | 12,683 | 16,751 (0%) | 0% | 154.3 | 1,956,733 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 153.38 per share. | 28 Feb 2023 | 850 | 809 (0%) | 0% | 153.4 | 130,373 | Common Stock, $0.01 par value |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 33,760 | 33,760 | - | - | Option (Right to buy) | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 18,715 | 19,524 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 4,366 | 23,890 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 3,146 | 27,036 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Scott Reents | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 2,398 | 29,434 (0%) | 0% | 0 | Common Stock, $0.01 par value |